Abstract: An infant carrier assembly may be removably securable to a car seat. The infant carrier assembly may include an adapter and an infant carrier. The adapter is removably securable to the car seat. The infant carrier is removably securable to the car seat by engagement with the adapter. A car seat assembly may include a car seat and the infant carrier assembly.

Abstract: An infant carrier assembly may be removably securable to a car seat. The infant carrier assembly may include an adapter and an infant carrier. The adapter is removably securable to the car seat. The infant carrier is removably securable to the car seat by engagement with the adapter. A car seat assembly may include a car seat and the infant carrier assembly.

Abstract: An infant carrier assembly may be removably securable to a car seat. The infant carrier assembly may include an adapter and an infant carrier. The adapter is removably securable to the car seat. The infant carrier is removably securable to the car seat by engagement with the adapter. A car seat assembly may include a car seat and the infant carrier assembly.

Abstract: A car seat assembly includes a car seat and an accessory. The car seat includes a base defining a right receiver port and a left receiver port. The accessory includes a right clip and a left clip removably securable within the respective right and left receiver ports to removably secure the accessory to the car seat. A method for securing the accessory to the car seat includes aligning the right and left clips with the respective right and left receiver ports. The method further includes introducing the right and left clips into the respective right and left receiver ports. The method further includes pushing the accessory toward the car seat until the right and left clips are secured within the respective right and left receiver ports.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: The invention provides combinations comprising a MERTK inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor and methods of use thereof, including methods of treating disorders such as cancer.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: The invention provides combinations comprising a MERTK inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor and methods of use thereof, including methods of treating disorders such as cancer.

Abstract: The present invention is directed to methods of treating a tumor, in particular human tumors, including administering an effective amount of a MER tyrosine kinase inhibitor (MER TKI) to inhibit TKI signaling in a tumor. The use of a MER TKI in combination with a chemotherapeutic agent, wherein the MER TKI can be administered to a host with a cancer prior to, during, or after administration with a chemotherapeutic agent, provides for increased anti-tumor effects without an increase in the standard of care dosage of the chemotherapeutic agent.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.

Abstract: Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.

Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.

Abstract: The invention provides methods of treating neoplastic disorders in a mammal through the inhibition of Mer and/or AxI receptor tyrosine kinases as well as compounds and compositions useful for inhibiting these kinases in these methods. These treatment methods may be combined with the administration of one or more chemo therapeutic agent(s) to enhance the efficacy or minimize the toxicities of the chemotherapeutic agent(s).